Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.40 |
| ▸ | VEGFA | P15692 | 2/20 | 0.40 |
| ▸ | ARNT | P27540 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13140964 | 0.96 | KCNH2 (0.42) | KCNH2HSP90AA1EPAS1VEGFAARNT | |
| SCHEMBL13119743 | 0.89 | KCNH2 (0.43) | KCNH2HSP90AA1EPAS1VEGFAARNT | |
| SCHEMBL3607303 | 0.85 | PDE4A (0.44) | HSP90AA1EPAS1VEGFA | |
| SCHEMBL13119754 | 0.85 | KCNH2 (0.36) | KCNH2HSP90AA1EPAS1VEGFAARNT | |
| SCHEMBL29817086 | 0.82 | TTR (0.43) | TTRALBKMT2AMEN1CA12 | |
| SCHEMBL508208 | 0.82 | TTR (0.43) | TTRALBKMT2AMEN1CA12 | |
| SCHEMBL6122883 | 0.82 | HSP90AA1 (0.54) | HSP90AA1CYP3A4KMT2AMEN1 | |
| SCHEMBL11222220 | 0.80 | HSP90AA1 (0.52) | HSP90AA1CYP3A4KMT2AMEN1MAPT | |
| SCHEMBL13119716 | 0.80 | KCNH2 (0.49) | KCNH2EPAS1VEGFAARNTCYP3A4 | |
| SCHEMBL12127662 | 0.80 | AR (0.47) | KCNH2EPAS1VEGFACYP3A4SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1910360-B1 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO INC (US) | 2010-03-03 | — | — | EP | disclosed |
| CN-101228120-A | HIV reverse transcriptase inhibitors | MERCK & CO INC (US) | 2008-07-23 | — | — | CN | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015812-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | KCNH2 3118/4885HSP90AA1 3071/4885EPAS1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.